NCT02305810View on ClinicalTrials.gov

A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus

PHASE2CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

January 12, 2017

Study Completion Date

June 30, 2018

Conditions
Pancreatic Neuroendocrine Tumour Metastatic
Interventions
DRUG

Everolimus 10 mg daily

everolimus is a recently approved mTOR inhibitor in advanced progressing well/moderately differentiated pancreatic neuroendocrine tumors

Trial Locations (1)

Unknown

European Institute of Oncology, Milan

All Listed Sponsors
lead

European Institute of Oncology

OTHER

NCT02305810 - A Biological Prospective Study in Patients With Metastatic Pancreatic NETs Treated With Everolimus | Biotech Hunter | Biotech Hunter